Walgreen (WAG) announced its quarterly results on Wednesday. The company reported $0.63 earnings per share for the quarter, missing the Thomson Reuters consensus estimate of $0.67 by $0.04. The company’s quarterly revenue was up 4.7% on a year-over-year basis.
On a related note, analysts at UBS AG (NYSE: UBS) cut their price target on shares of Walgreen to $40.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Analysts at Macquarie initiated coverage on shares of Walgreen in a research note to investors on Monday. They set a “neutral” rating on the stock. Also, analysts at Barclays Capital (NYSE: BCS) reiterated an “underweight” rating on shares of Walgreen in a research note to investors on Friday, December 16th.
Shares of Walgreen (WAG) opened at 33.50 on Wednesday. Walgreen (WAG) has a 52 week low of $30.34 and a 52 week high of $47.11. The stock’s 50-day moving average is $33.01 and its 200-day moving average is $36.52. The company has a market cap of $29.791 billion and a price-to-earnings ratio of 11.39.
Walgreen Co. (Walgreen) together with its subsidiaries, operates a drugstore chain in the United States. The Company provides its customers with multichannel access to consumer goods and services, and pharmacy, health and wellness services in communities across America. Walgreen offers its products and services through drugstores, as well as through mail, by telephone, and via the Internet. It sells prescription and non-prescription drugs, as well as general merchandise, including household products, convenience foods, personal care, beauty care, candy, photofinishing and seasonal items. Its pharmacy services includes retail, specialty, infusion, medical facility, long- term care and mail service, along with pharmacy benefit solutions and respiratory services. In January 2010, the Company announced that it has completed the acquisition of the assets of 12 Eaton Apothecary pharmacies in the Boston area from D.A.W., Inc., a subsidiary of Nyer Medical Group, Inc.
Stay on top of analysts' coverage with our daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day. Click here to register.